Search
Lacidipine
go.drugbank.com/drugs/DB09236ApprovedIt is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesProducts: LACIDIPINA EG, LACIPIL TABLET 4 mgDimetindene
go.drugbank.com/drugs/DB08801ApprovedInvestigationalDimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.
Categories: Heterocyclic Compounds, 1-Ring, Antihistamines, Anesthetics, Etc.Products: Dimestil 1 mg/g Gel, Fenistil 1 mg - DrageesMeperidine
go.drugbank.com/drugs/DB00454ApprovedInvestigationalA narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor.
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein substratesProducts: ALDOLAN 100 MG/2 ML AMPUL, 5 ADET, PETHOLAN 100 MG/2 ML ENJEKSIYONLUK ÇÖZELTI, 5 ADETBuserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalIt is used in prostate cancer treatment. … Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).
Products: SUPREFACT INJECTABLE 1 mg/ml, Suprefact 1 mg/ml DurchstechflascheTocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: ACTEMRA 200 MG/10 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 1 ADET, ACTEMRA 80 MG/4 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 1 ADETLevamisole
go.drugbank.com/drugs/DB00848ApprovedInvestigationalVet approvedWithdrawn[A178123] Interestingly, levamisole has been found as an adulterant in cocaine and can lead to a variety of adverse effects in individuals using this drug.[A178120] … [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranulocytosis.
Categories: Heterocyclic Compounds, 1-RingProducts: PARAKS 40 MG/5 ML ŞURUP, 30 ML, SITRAKS 40 MG/5 ML SURUP, 30 MLIndopan
go.drugbank.com/drugs/DB01446ExperimentalIllicitIt was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states. … Indopan (alpha-methyltryptamine) is a stimulant and psychoactive drug which produces effects similar to 3,4-methylenedioxy-N-methylamphetamine (MDMA), despite being structurally dissimilar.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Heterocyclic Compounds, 2-RingSynonyms: DL-3-(2-Aminopropyl)indole, 1-(1H-Indol-3-yl)-2-propanamineDimercaptosuccinic acid
go.drugbank.com/drugs/DB14089ApprovedInvestigationalCategories: Compounds used in a research, industrial, or household settingProducts: MON.DMSA KIT 1 MG IV ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON, 5 ADETGinkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceuticalLactones include ginkgolide A, ginkgolide B, ginkgolide C, bilobalide, and ginkgotoxin, a lactone that is structurally related to [pyridoxine]. … _Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA
Mixtures: DOMINGO 5/5/80 MG EFERVESAN TABLET, 30 ADET, DOMINGO 5/5/80 MG EFERVESAN TABLET, 90 ADETCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 CYP3A InducersDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 mg/2ml, DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml